News Briefing channel feed

Lil­ly pledges more than $650M to mus­cle health biotech; Co­gent gets $50M

21 hours ago

In­smed’s stock ral­lies on PAH da­ta; Uni­cy­cive aims to re­solve CD­MO is­sues

Yesterday

Avid­i­ty to seek ac­cel­er­at­ed ap­proval for FSHD drug; Ax­some to run an­oth­er tri­al

2 days ago

Kelun's $250M PIPE; Val­ne­va moves chikun­gun­ya vac­cine to Phase 3 for kids

5 days ago

Cul­li­nan's deal for T cell en­gager from Chi­na; Kardi­gan buys late-stage heart drug

6 days ago

Vig­il drug fails a Phase 2; Merus aims to raise $300M

Last week

Ve­ra re­draws the terms of up to $500M cred­it fa­cil­i­ty; Tre­vi aims to raise $100M

Last week

Sanofi pays out two STAT6 mile­stones; Ther­a­vance sells more Trel­e­gy roy­al­ties

Last week

Roche’s 96-week da­ta for mul­ti­ple scle­ro­sis drug; ZymeWorks claims $20M mile­stone

Last week

Taysha’s piv­otal tri­al plans; Keros to stop work on PAH drug, lay off 45% of staff

Last week

Veru’s obe­si­ty drug rough­ly as safe as We­govy; Keros’ board fight

2 weeks ago

ITM re­veals up to $262M debt fi­nanc­ing; Caris Life Sci­ences to go pub­lic

3 weeks ago

GLP-1s may cut can­cer risk; Gyre’s stock falls af­ter hep B da­ta and of­fer­ing

3 weeks ago

Mod­er­na pulls ap­pli­ca­tion for Covid-flu shot; An­oth­er IPO in Hong Kong

3 weeks ago

SV Health’s $269M de­men­tia fund; Schrödinger lays off 7% of staff

4 weeks ago

Io­n­is de­tails late-stage da­ta for heart drug; Ar­ma­ta’s promis­ing staph in­fec­tion ther­a­py

4 weeks ago

FDA lifts hold on Scynex­is tri­al; In­cyte’s Zynyz notch­es an­oth­er FDA ap­proval

4 weeks ago

En­liv­en stops work on sol­id tu­mor drug; Pul­ma­trix to di­vest as­sets

4 weeks ago

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

4 weeks ago

Ax­some's $570M loan with Black­stone; Al­tim­mune makes its own cred­it deal

5 weeks ago

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

5 weeks ago

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Last month

ALX On­col­o­gy won’t seek ap­proval for CD47 drug in gas­tric can­cer; Ko­r­ro Bio’s lay­offs

Last month

Eu­ro­pean reg­u­la­tors to re­view Val­ne­va shot; Jaz­z's stock dips on sub­par first-quar­ter rev­enue

Last month
1234 Next page Last page
A service from the Financial Times